MedElevator
Войти в исследования Dermatology and therapy · 2026
Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kieffer Camille, Hebert Vivien, Joly Pascal, Tedbirt Billal
Аннотация
INTRODUCTION: While rituximab has been approved for moderate-to-severe pemphigus vulgaris, data on pemphigus foliaceus (PF) remain limited because of the small number of patients included in therapeutic trials. However, current European guidelines recommend rituximab for the first-line treatment of patients with moderate-to-severe PF. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of rituximab in PF.
METHODS: This systematic review and meta-analysis was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023428459). Studies published in English that included ≥ 3 patients with PF treated with rituximab were identified through six databases up to May 2025. Data on patient characteristics, rituximab regimens, clinical status at the end of follow-up, relapse rates, and severe adverse events (SAEs) were extracted.
RESULTS: Twenty-four studies, published between 2012 and 2025, including 195 patients with PF, were analyzed. Mean age was 48.8 ± 20.8 years, and median follow-up was 24.5 months (interquartile range [IQR] 19-32.7). Rituximab was used as first-line therapy in 21% and as second-line therapy in 46.7% of patients (data not reported for 32.3% of patients), most frequently combined with oral corticosteroids (69.7%). The pooled complete remission (CR) rate was 75.0% (95% confidence interval (CI) 64.0-83.0; I2 = 35.5%), with a median time to CR of 9 months (IQR 3.8-14.0). No significant difference was found between the lymphoma- and the rheumatoid arthritis-type regimens (p = 0.80). The pooled relapse rate was 38.0% (95% CI 26.0-51.0; I2 = 37.8%), occurring with a median time to relapse of 12.5 months (IQR 10.25-24.5) after the first cycle of rituximab treatment. Twenty SAEs were reported, mainly infections (65%).
CONCLUSIONS: Rituximab appears to be a safe and effective treatment for PF. These findings support its use as first-line therapy in moderate-to-severe PF.
METHODS: This systematic review and meta-analysis was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023428459). Studies published in English that included ≥ 3 patients with PF treated with rituximab were identified through six databases up to May 2025. Data on patient characteristics, rituximab regimens, clinical status at the end of follow-up, relapse rates, and severe adverse events (SAEs) were extracted.
RESULTS: Twenty-four studies, published between 2012 and 2025, including 195 patients with PF, were analyzed. Mean age was 48.8 ± 20.8 years, and median follow-up was 24.5 months (interquartile range [IQR] 19-32.7). Rituximab was used as first-line therapy in 21% and as second-line therapy in 46.7% of patients (data not reported for 32.3% of patients), most frequently combined with oral corticosteroids (69.7%). The pooled complete remission (CR) rate was 75.0% (95% confidence interval (CI) 64.0-83.0; I2 = 35.5%), with a median time to CR of 9 months (IQR 3.8-14.0). No significant difference was found between the lymphoma- and the rheumatoid arthritis-type regimens (p = 0.80). The pooled relapse rate was 38.0% (95% CI 26.0-51.0; I2 = 37.8%), occurring with a median time to relapse of 12.5 months (IQR 10.25-24.5) after the first cycle of rituximab treatment. Twenty SAEs were reported, mainly infections (65%).
CONCLUSIONS: Rituximab appears to be a safe and effective treatment for PF. These findings support its use as first-line therapy in moderate-to-severe PF.